David S. Siegel, MD, PhD
If a patient with multiple myeloma progresses on a lenalidomide (Revlimid)-based regimen, it does not mean oncologists should completely forgo the class of immunomodulatory (IMiD) agents, according to David S. Siegel, MD, PhD.
When patients become refractory to certain drugs, physicians may believe they need to move on to a different class of agents, he added. However, a study presented at the 2018 ASH Annual Meeting challenged this hypothesis.
In the trial, patients who progressed on lenalidomide were treated with a pomalidomide (Pomalyst)-based regimen. Results showed that the overall response rate (ORR) was 77.7%, with 33.9% of patients demonstrating a very good partial response or better. The clinical benefit rate was 85.7%. The ORR was 80.6% in the efficacy-evaluable population, 75.0% in lenalidomide-refractory patients, and 76.2% in patients with 2 prior lines of therapy. The 9-month progression-free survival (PFS) rate was 86.3%.
... to read the full story